Nisha Andany, MD, MPH, FRCPC

Infectious Disease Specialist
Sunnybrook Health Sciences Centre

Disclosure: Gilead Sciences (Individual(s) Involved: Self): Scientific Research Study Investigator; GlaxoSmithKline (Individual(s) Involved: Self): Scientific Research Study Investigator; Janssen (Individual(s) Involved: Self): Scientific Research Study Investigator

Presentation(s):

• 116 - Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study

  Oral Abstract